Skip to main content

CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19

Written by Customer Service on . Posted in Public Companies.

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced that its paper ‘Rapid Large-Scale COVID-19 Testing During Shortages’ has been published in Diagnostics (www.mdpi.com/journal/diagnostics), an international peer-reviewed open access journal on medical diagnosis. The paper describes innovative testing solutions in the fight against COVID-19 pandemic and contributes to the global understanding of the novel Coronavirus. Furthermore, it discusses the Company’s science-backed Coronavirus initiatives, and how these can provide a testing blueprint for the medical community.
Prof. Arndt Rolfs, CEO of CENTOGENE, said, “Over the past months, we have been working tirelessly to ensure that we are providing the highest standards of molecular diagnostic testing that can support widescale testing of SARS-CoV-2. Maintaining our commitment to developing solutions that keep patients at the forefront, we leveraged our medical expertise to provide rapid and reliable diagnostic solutions on a large scale amid this global outbreak. The holistic solution is also the basis for our service to airport based mobility, like at the Frankfurt airport. We are proud that we can now share these insights – enabling necessary joint efforts to provide preventative testing and a return to a new normal.”“At CENTOGENE, we pride ourselves on providing our patients with diagnostic tests they can trust,” adds Dr Florian Vogel, SVP Clinical Lab Operations. “With our recent COVID-19 testing initiative, we have demonstrated that even during resource shortages, it is possible to rapidly develop and deliver high quality testing under WHO/CDC Guidelines.”About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.CENTOGENE Contact:
Ben Legg
Corporate Communications

Media Contact:
FTI Consulting
Bridie Lawlor
+1.917.929.5684

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.